Premier Biomedical Inc (PK:BIEI)

Business Focus: Biotechnology & Medical Research

Sector:  Healthcare Industry:  Biotechnology & Medical Research
See Regulatory Filings on SEC
Company Contact
Address: PO Box 25
Tel: N/A
IR: See website
Key People
Mitchell S. Felder
Independent Chairman of the Board, Scientific Advisory Board
William A Hartman
President, Chief Executive Officer, Director
Heidi H. Carl
Chief Financial Officer, Treasurer, Secretary, Director
Patricio F. Reyes
Chief Technology Officer, Director
Business Overview
Premier Biomedical, Inc. is a research-based company that intends to discover and develop medical treatments for humans, specifically focusing the treatment of Cancer, Multiple Sclerosis (MS), Neuropathic Pain, Amyotrophic Lateral Sclerosis (ALS/Lou Gehrig's Disease), Fibromyalgia, Traumatic Brain Injury (TBI), Alzheimer's disease (AD), and Blood Sepsis and Viremia. The Company intends to develop its Sequential-Dialysis Technique, to target Cancer, Alzheimer's disease, ALS, Blood Sepsis, Leukemia and other life-threatening cancers. The Sequential-Dialysis Technique is a methodology for the removal of those molecules, which are harmful and responsible for causing diseases. Its Sequential-Dialysis Technique method removes those excitatory neural transmitters that cause the death of those cells. It also intends to develop Feldetrex, a candidate drug, for the treatment of MS, Fibromyalgia and TBI. Feldetrex utilizes a low dosage of Naltrexone to increase endogenous enkephalins10.
Financial Overview
For the nine months ended 30 September 2019, Premier Biomedical Inc revenues decreased 58% to $13K. Net loss totaled $340K vs. income of $103K. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Net loss reflects Change in derivative liabilities decrease from $656K (income) to $19K (expense).
Reporting Currency: U.S. Dollars
Enterprise value: $0.15M as of Sep 30, 2019
Annual revenue (TTM): $0.02M as of Sep 30, 2019
EBITDA (TTM): -$0.68M as of Sep 30, 2019
Net annual income (TTM): -$0.84M as of Sep 30, 2019
Free cash flow (TTM): -$0.40M as of Sep 30, 2019
Net Debt Last Fiscal Year: $0.08M as of Sep 30, 2019
Shares outstanding: 186,961,480 as of Nov 12, 2019
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization